Shares of Alvotech fell 33% on November 3, 2025, after the company received a complete response letter from the FDA for its biologics license application for AVT05. The CRL relates to a failed facility inspection which occurred in July 2025. Block & Leviton is investigating the Company’s disclosures.
Contact our attorneys for a no-cost case evaluation.